Nektar Therapeutics and Jonathan Zalevsky, PhD, are exploring REZPEG's potential in treating alopecia, atopic dermatitis, lupus, and diabetes, aiming for groundbreaking autoimmune therapies.
Jonathan Zalevsky, PhD
Advertisement
Articles by Jonathan Zalevsky, PhD
Nektar Therapeutics explores rezpegaldesleukin's potential as a groundbreaking treatment for alopecia areata, aiming for FDA approval and improved patient outcomes.
Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.
Jonathan Zalevsky, PhD, discusses the fundamentally different path of Rezpeg compared with existing IL-4 and IL-13 inhibitors in atopic dermatitis.
Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.
Advertisement
Latest Updated Articles
Tackling Unmet Needs in Dermatology With RezpegaldesleukinFebruary 18th 2025
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
5